Patent intelligence · US
US 12017030
Hydrogen-enhanced transdermal system
Hydrogen-enhanced transdermal system
Patent details — US 12017030
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jun 25, 2024
- Expiration
- Jun 20, 2044
- Applicant
- H2 Universe LLC
- Claims
- 20
- CPC classes
- A61K, A61K47/02, A61K9/0004, A61K9/0014
Quick answer
US 12017030 (Hydrogen-enhanced transdermal system) is held by H2 Universe LLC. Status: granted. Granted Jun 25, 2024. Expires Jun 20, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- H2 Universe LLC
- Grant date
- Expiration
- Claims
- 20
- CPC classes
- A61K, A61K47/02, A61K9/0004, A61K9/0014, A61K9/7084
More from H2 Universe LLC
Related pharmaceutical patents in our USPTO index.
Frequently asked questions
What is US patent 12017030?
US 12017030 (Hydrogen-enhanced transdermal system) is held by H2 Universe LLC. Status: granted. Granted Jun 25, 2024. Expires Jun 20, 2044 (18 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12017030?
H2 Universe LLC is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 5 pharmaceutical patents for this assignee.
When does US 12017030 expire?
Our index shows an expiration date of Jun 20, 2044 (18 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.